Janux Therapeutics, Inc. (JANX) P/S ratio

P/S ratio today
66.4×

Janux Therapeutics, Inc. (JANX) trades at 66.4× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 85.5×. That is 68.5% lower than the 271.8× of fiscal 2024. Figures as of 18 Nov 2026, 10:33 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

P/S ratio today
66.4×
P/S ratio, fiscal 2025
85.5×
Change on fiscal 2024
−68.5%
Highest on record
271.8×fiscal 2024
Lowest on record
58.4×fiscal 2023
Fiscal years on record
42022–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Janux Therapeutics, Inc. P/S ratio, in more detail

Today's figure is 22.4% below the fiscal 2025 year-end.

Across the 4 fiscal year-ends on record (2022–2025), the highest was 271.8× in fiscal 2024 and the lowest 58.4× in fiscal 2023. Today's P/S ratio is higher than at 50% of the 4 fiscal year-ends on record; their median is 74.5×.

History · 4 fiscal years

P/S ratio at each fiscal year-end

The last point is today's figure; the others are fiscal year-ends.

Janux Therapeutics, Inc. P/S ratio, year by year

Janux Therapeutics, Inc. (JANX) P/S ratio by fiscal year
Fiscal yearP/S ratioChangeYear endedShare price at year-endRevenue per share
Today66.4×—$10.71—
202585.5× 68.5% down$13.80$0.16
2024271.8× 365.2% up$53.54$0.20
202358.4× 7.9% down$10.73$0.18
202263.4×—$13.17$0.21
2021——$19.73—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

How to read it

It prices each unit of sales and still works when there is no profit; what counts as high depends on the margin those sales earn.

More on JANX

Janux Therapeutics, Inc., figure by figure

Janux Therapeutics, Inc. (JANX) overview: price, valuation and scorecard

Janux Therapeutics, Inc. P/S ratio: questions and answers

What is Janux Therapeutics, Inc.'s P/S ratio?

Janux Therapeutics, Inc. (JANX) trades at 66.4× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 85.5×. That is 68.5% lower than the 271.8× of fiscal 2024.

Is Janux Therapeutics, Inc.'s P/S ratio high or low compared with its own history?

Today's P/S ratio is higher than at 50% of the 4 fiscal year-ends on record; their median is 74.5×.

What are the highest and lowest P/S ratio figures on record for Janux Therapeutics, Inc.?

Across the 4 fiscal year-ends on record (2022–2025), the highest was 271.8× in fiscal 2024 and the lowest 58.4× in fiscal 2023.

How is Janux Therapeutics, Inc.'s P/S ratio calculated?

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end. For Janux Therapeutics, Inc. it is on record here for 4 fiscal years, 2022 to 2025.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Janux Therapeutics, Inc. (JANX) P/S ratio”, data as of 18 November 2026. https://funkfolio.com/stock/JANX/ps-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.